检索结果-南通市图书馆

Effect and Safety of Herbal Medicine Foot Baths in Patients with Diabetic Peripheral Neuropathy:A Multicenter Double-Blind Randomized Controlled Trial

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Integrative Medicine 2024年第3期30卷 195-202页

作者： HUANG Hao-yue LIN Yu-ping wei Hua fu Yu ZHOU Yue-hong FANG Zhao-hui QIU xiao-tang WANG Mei LI Qing-bo LI shan-shan WANG Shi-dong DAI Fang LIU Zhen-jie ZHAO Ling WEN Jian-xuan WU Li-yan ZENG Hui-yan ZHANG Jin-ming LU Qi-yun HE Liu SONG wei SUN Lu luo Lu-lu HE Jia-li XIE Wen-wen LIANG Qing-shun HUANG yuan ZHU Sheng-ling LONG Jie-er GAO zhi-juan WEN Ze-huai LI Chun-ji OUYANG Wen-wei LI Geng WU Ming-hui LI An-xiang HUANG Jin-zhu Sanjoy K Paul TANG Xian-yu FAN Guan-jie Department of Endocrinology Guangdong Provincial Hospital of Chinese MedicineGuangzhou510120China The Second Clinical College of Guangzhou University of Chinese Medicine Guangzhou510120China Department of Endocrinology The Second Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou510120China Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou510120China Department of Endocrinology The First Affiliated Hospital of Henan University of Chinese MedicineZhengzhou450000China Department of Endocrinology Liuyang Hospital of Chinese MedicineChangsha410000China Department of Endocrinology The First Affiliated Hospital of Anhui University of Chinese MedicineHefei230000China Department of Endocrinology Hainan Provincial Hospital of Traditional Chinese MedicineHaikou570100China Department of Endocrinology The Affiliated Hospital of Liaoning University of Traditional Chinese MedicineShenyang110000China Department of Geriatric Luoyang No.1 Hospital of Traditional Chinese MedicineLuoyangHenan Province471000China Department of Endocrinology The Second Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Department of Endocrinology Beijing University of Chinese Medicine Affiliated Dongzhimen HospitalBeijing100000China Department of Endocrinology The First Affiliated Hospital of Guizhou University of Traditional Chinese MedicineGuiyang550000China Melbourne EpiCentre The University of Melbourne and Melbourne HealthMelbourne3013Australia

Objective:To evaluate the effect and safety of foot baths with Tangbi Waixi Decoction(TW)in treating patients with diabetic peripheral neuropathy(DPN).Methods:It is a multicenter double-blinded randomized controlled *** with DPN were recruited between November 18,2016 and May 30,2018 from 8 hospitals in *** patients received basic treatments for glycemic *** received foot baths with TW herbal granules either 66.9 g(intervention group)or 6.69 g(control group)for 30 min once a day for 2 weeks and followed by a 2-week rest,as a therapeutic *** the Toronto Clinical Scoring System total score(TCSS-TS)6 points,the patients received a total of 3 therapeutic courses(for 12 weeks)and were followed up for 12 *** primary outcome was change in TCSS-TS score at 12 and 24 *** outcomes included changes in bilateral motor nerve conduction velocity(MNCV)and sensory nerve conduction velocity(SNCV)of the median and common peroneal *** was also ***:Totally 632 patients were enrolled,and 317 and 315 were randomized to the intervention and control groups,*** the 12-week intervention,patients in both groups showed significant declines in TCSSTS scores,and significant increases in MNCV and SNCV of the median and common peroneal nerves compared with pre-treatment(P0.05),and no serious adverse event was related with ***:Treatment of TW foot baths was safe and significantly benefitted patients with DPN.A low dose of TW appeared to be more effective than a high dose.(Registry *** CTR-IOR-16009331)

关键词： diabetic peripheral neuropathy herbal medicine foot baths Chinese medicine randomized controlled trial Tangbi Waixi Decoction

CEPC Technical Design Report

在线全文

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci xiao-Jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi Junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen Danping Chen fuqing Chen fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen shanhong Chen shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen wei Chen xiang Chen xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu Guk Cho Ming-Chung Chu xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-Yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng wei-Tian Deng zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi Dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng Ying-Hui Jin Tong-Zu Liu Fang-Ming Chen De-Gang Ding Meng fu Xin-Quan Gu Bang-Min Han Xing Huang zhi Hou Wan-Li Hu Xin-Li Kang Gong-Hui Li Jian-Xing Li Pei-Jun Li Chao-Zhao Liang Xiu-Heng Liu zhi-Yu Liu Chun-xiao Liu Jiu-Min Liu Guang-Heng luo Yi luo wei-Jun Qin Jian-Hong Qiu Jian-Xin Qiu Xue-Jun shang Ben-Kang Shi Fa Sun Guo-xiang Tian Ye Tian Feng Wang Feng Wang Yin-Huai Wang Yu-Jie Wang zhi-Ping Wang Zhong Wang Qiang wei Min-Hui xiao Wan-Hai Xu Fa-Xian Yi Chao-Yang Zhu Qian-yuan Zhuang Li-Qun Zhou xiao-Feng Zou Nian-Zeng Xing Da-Lin He Xing-Huan Wang 无 Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China Department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China Department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China Department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China Department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China Department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China Department of Urology Qinghai University Affiliated HospitalXi’ning810012China Department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China Department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China Department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China Department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China Department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina Department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China Department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China Department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China Department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China Department of Urology

Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia Recommendation Treatment Guideline

A practical community-based response strategy to interrupt Ebola transmission in sierra Leone, 2014–2015

在线全文

学校读者我要写书评

暂无评论

Infectious Diseases of Poverty 2016年第1期5卷 670-679页

作者： Zhong-Jie Li Wen-xiao Tu xiao-Chun Wang Guo-Qing Shi Zun-Dong Yin Hai-Jun Su Tao Shen Da-Peng Zhang Jian-Dong Li shan Lv Chun-Li Cao Rui-Qian Xie Hong-Zhou Lu Rong-Meng Jiang Zheng Cao zhi-Jie An Lei-Lei Li Jie Xu Yan-Wen Xiong wei Zang wei Zhang Hong-wei Zhang Wen-Sen Chen Hua Ling Wen Xu Jian Cai Huan-Jin luo Xue-Sheng Xing Can-Jun Zheng Qiang wei Xin-Xu Li Mei Li Hai Jiang Li-Quan Deng Ming-Quan Chen xiang Huo Feng Xu Xue-Hui Lai Xi-Chen Bai Long-Jie Ye Jian-Yi Yao Wen-Wu Yin Jiao-Jin Sun Lin xiao fu-Qiang Liu xiao-Qiang Liu Hong-wei Fan Zeng-Qiang Kou Ji-Kun Zhou Hao Zhang Da-Xin Ni Thomas TSamba Qun Li Hong-Jie Yu Yu Wang xiao-Feng Liang Division of Infectious Disease Key Laboratory of Surveillance and Early-warning on Infectious DiseaseChinese Center for Disease Control and PreventionBeijingChina Public Health Emergency Center Chinese Center for Disease Control and PreventionBeijingChina National Center for AIDS/STD Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Chinese Field Epidemiology Training Program Chinese Center for Disease Control and PreventionBeijingChina National Immunization Program Chinese Center for Disease Control and PreventionBeijingChina Bureau of Disease Prevention and Control National Health and Family Planning Commission of the People’s Republic of ChinaBeijingChina National Institute for Viral Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina National Institute of Parasitic Disease Chinese Center for Disease Control and PreventionShanghaiChina Chinese Center for Health Education BeijingChina Department of Infectious Diseases Shanghai Public Health Clinical CenterShanghaiChina Beijing Ditan Hospital Capital Medical UniversityBeijingChina Health News BeijingChina National Institute for Communicable Disease Control and Prevention Chinese Center for Disease Control and PreventionBeijingChina Department of Training Chinese Center for Health EducationBeijingChina Center for Infectious Diseases Beijing Youan HospitalCapital Medical UniversityBeijingChina Infection Management The First Affiliated Hospital of Nanjing Medical UniversityNanjingChina Chongqing Municipal Center for Disease Control and Prevention ChongqingChina Yunnan Provincial Center for Disease Control and Prevention KunmingChina Division of Infectious Disease Control and Prevention Zhejiang Provincial Center for Disease Control and PreventionHangzhouChina Guangdong Provincial Center for Disease Control and Prevention GuangzhouChina Division of Acute Infectious Disease Control and Prevention Hubei Provincial Center for Disease Control and PreventionW

Background:The Ebola virus disease spread rapidly in West Africa in 2014,leading to the loss of thousands of *** engagement was one of the key strategies to interrupt Ebola transmission,and practical community level measures needed to be explored in the field and tailored to the specific context of ***:First,community-level education on Ebola virus disease(EVD)prevention was launched for the community’s social mobilizers in six districts in Sierra Leone beginning in November ***,from January to May of 2015,in three pilot communities,local trained community members were organized to engage in implementation of EVD prevention and transmission interruption measures,by involving them in alert case report,contact tracing,and social *** epidemiological indicators of transmission interruption in three study communities were ***:A total of 6016 community social mobilizers from 185 wards were trained by holding 279 workshops in the six districts,and EVD message reached an estimated 631680 *** three pilot communities,72 EVD alert cases were reported,with 70.8%of them detected by trained local community members,and 14 EVD cases were finally *** tracing detected 64.3%of EVD *** median duration of community infectivity for the cases was 1 *** secondary attack rate was 4.2%,and no third generation of infection was *** health worker was infected,and no unsafe burial and noncompliance to EVD control measures were *** community-based measures were modeled to reduce 77 EVD cases,and the EVD-free goal was achieved four months earlier in study communities than whole country of Sierra ***: The community-based strategy of social mobilization and community engagement was effective in casedetection and reducing the extent of Ebola transmission in a country with weak health system. The successfullypractical experience to reduce the risk of Ebola transmission in the

关键词： Ebola virus disease Community engagement Health education Outbreak control

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline(updated version)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military Medical Research 2020年第3期7卷 249-282页

作者： Ying-Hui Jin Qing-yuan Zhan zhi-Yong Peng Xue-Qun Ren Xun-Tao Yin Lin Cai Yu-Feng yuan Ji-Rong Yue xiao-Chun Zhang Qi-Wen Yang Jianguang Ji Jian Xia Yi-Rong Li fu-xiang Zhou Ya-Dong Gao Zhui Yu Feng Xu Ming-Li Tu Li-Ming Tan Min Yang Fang Chen xiao-Ju Zhang Mei Zeng Yu Zhu Xin-Can Liu Jian Yang Dong-Chi Zhao Yu-Feng Ding Ning Hou fu-Bing Wang Hao Chen Yong-Gang Zhang wei Li Wen Chen Yue-Xian Shi Xiu-zhi Yang Xue-Jun Wang Yan-Jun Zhong Ming-Juan Zhao Bing-Hui Li Lin-Lu Ma Hao Zi Na Wang Yun-Yun Wang Shao-fu Yu Lu-Yao Li Qiao Huang Hong Weng xiang-Ying Ren Li-Sha luo Man-Ru Fan Di Huang Hong-Yang Xue Lin-Xin Yu Jin-Ping Gao Tong Deng Xian-Tao Zeng Hong-Jun Li Zhen-Shun Cheng xiao-Mei Yao Xing-Huan Wang Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Respiratory Diseases China-Japan Friendship HospitalBeijing 100029China Department of Pulmonary and Critical Care Medicine China-Japan Friendship HospitalBeijing 10029China Leishenshan Hospital in Wuhan Wuhan 430200China Department of Critical Care Medicine Zhongnan Hospital of Wuhan UniversityWuhan 430071China Institutes of Evidence-based Medicine and Knowledge Translation Henan UniversityKaifeng 475000HenanChina Department of Medical Imaging Guizhou Provincial People’s HospitalGuiyang 550002China Departments of Orthopedics Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery Zhongnan Hospital of Wuhan UniversityWuhan 430071China National Clinical Research Center for Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Geriatrics West China Hospital of Sichuan UniversityChengdu 610041China Department of Radiology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Clinical Laboratory Peking Union Medical College Hospital(PUMCH)Peking Union Medical CollegeChinese Academy of Medical Sciences(CAMS)Beijing 100730China Center for Primary Health Care Research Lund University and Region Skåne25002 MalmöSweden Emergency Center Zhongnan Hospital of Wuhan UniversityWuhan 403371China Department of Allergology Zhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Radiation and Medical Oncology Zhongnan Hospital of Wuhan UniversityWuhan 43071China Department of Critical Care Medicine Renmin Hospital of Wuhan UniversityWuhan 430060China Department of Emergency Medicine and Chest Pain Center Qilu Hospital of Shandong UniversityJinan 250002China Department of Respiratory and Critical Care Medicine Suizhou Central HospitalHubei University of MedicineSuizhou 441300HubeiChina Department of Clinic Pharmacy Second People’s Hospital of Huaihua Ci

The novel severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is the cause of a rapidly spreading illness,coronavirus disease 2019(COVID-19),affecting more than seventeen million people around the *** and treatment guidelines for clinicians caring for patients are *** the early stage,we have issued"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus(2019-nCoV)infected pneumonia(standard version)";now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based *** formed a working group of clinical experts and *** steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas:chemoprophylaxis,diagnosis,treatments,and discharge *** searched the literature for direct evidence on the management of COVID-19,and assessed its certainty generated recommendations using the Grading of Recommendations,Assessment,Development and Evaluation(GRADE)*** were either strong or weak,or in the form of ungraded consensus-based ***,we issued 34 *** them,6 were strong recommendations for,14 were weak recommendations for,3 were weak recommendations against and 11 were ungraded consensus-based *** covered topics of chemoprophylaxis(including agents and Traditional Chinese Medicine(TCM)agents),diagnosis(including clinical manifestations,reverse transcription-polymerase chain reaction(RT-PCR),respiratory tract specimens,IgM and IgG antibody tests,chest computed tomography,chest X-ray,and CT features of asymptomatic infections),treatments(including lopinavirritonavir,umifenovir,favipiravir,interferon,remdesivir,combination of antiviral drugs,hydroxychloroquine/chloroquine,interleukin-6 inhibitors,interleukin-1 inhibitors,glucocorticoid,qingfei paidu decoction,lianhua qingwen granules/capsules,convalescent plasma,lung

关键词： COVID-19 SARS-CoV-2 Recommendation Chemoprophylaxis Diagnosis Treatment Discharge management Traditional Chinese medicine guideline

Timing analysis of the black hole candidate EXO 1846–031 with Insight-HXMT monitoring

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2021年第3期21卷 193-204页

作者： He-Xin Liu Yue Huang Guang-Cheng xiao Qing-Cui Bu Jin-Lu Qu Shu Zhang Shuang-Nan Zhang Shu-Mei Jia Fang-Jun Lu xiang Ma Lian Tao wei Zhang Li Chen Li-Ming Song Ti-Pei Li Yu-Peng Xu Xue-Lei Cao Yong Chen Cong-Zhan Liu Ce Cai zhi Chang Gang Chen Tian-xiang Chen Yi-Bao Chen Yu-Peng Chen wei Cui wei-wei Cui Jing-Kang Deng Yong-wei Dong yuan-yuan Du Min-Xue fu Guan-Hua Gao He Gao Min Gao Ming-Yu Ge Yu-Dong Gu Ju Guan Cheng-Cheng Guo Da-wei Han Jia Huo Lu-Hua Jiang wei-Chun Jiang Jing Jin Yong-Jie Jin Ling-Da Kong Bing Li Cheng-Kui Li Gang Li Mao-Shun Li wei Li Xian Li xiao-Bo Li Xu-Fang Li Yang-Guo Li Zheng-wei Li xiao-Hua Liang Jing-yuan Liao Bai-Sheng Liu Guo-Qing Liu Hong-wei Liu xiao-Jing Liu Yi-Nong Liu Bo Lu Xue-Feng Lu Qi luo Tao luo Bin Meng Yi Nang Jian-Yin Nie Ge Ou Na Sai Ren-Cheng shang Xin-Ying Song Liang Sun Ying Tan You-Li Tuo Chen Wang Guo-Feng Wang Juan Wang Ling-Jun Wang Weng-Shuai Wang Yu-Sa Wang xiang-Yang Wen Bai-Yang Wu Bo-Bing Wu Mei Wu Shuo xiao Shao-Lin Xiong He Xu Jia-wei Yang Sheng Yang Yan-Ji Yang Yi-Jung Yang Qi-Bin Yi Qian-Qing Yin yuan You Ai-Mei Zhang Cheng-Mo Zhang Fan Zhang Hong-Mei Zhang Juan Zhang Tong Zhang Wan-Chang Zhang Wen-Zhao Zhang Yi Zhang Yi-Fei Zhang Yong-Jie Zhang yuan-Hang Zhang Yue Zhang Zhao Zhang zhi Zhang Zi-Liang Zhang Hai-Sheng Zhao xiao-Fan Zhao Shi-Jie Zheng Yao-Guang Zheng Deng-Ke Zhou Jian-Feng Zhou Yu-Xuan Zhu Ren-Lin Zhuang Yue Zhu Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China University of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Institut fur Astronomie und Astrophysik Kepler Center for Astro and Particle PhysicsEberhard Karls Universität72076 TubingenGermany Department of Astronomy Beijing Normal UniversityBeijing 100088China Department of Astronomy Tsinghua UniversityBeijing 100084China Department of Physics Tsinghua UniversityBeijing 100084China Department of Engineering Physics Tsinghua UniversityBeijing 100084China Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China College of Physics Sciences&Technology Hebei UniversityBaoding 071002Hebei ProvinceChina

We present the observational results from a detailed timing analysis of the black hole candidate EXO 1846-031 during its outburst in 2019 with the observations of Insight-HXMT,NICER and *** outburst can be classified roughly into four different ***-C quasi-periodic oscillations(QPOs)observed by NICER(about 0.1-6 Hz)and Insight-HXMT(about 0.7-8 Hz)are also reported in this ***,we study various physical quantities related to QPO *** QPO rms-frequency relationship in the energy band 1-10 keV indicates that there is a turning pointing in frequency around2 Hz,which is similar to that of GRS 1915+105.A possible hypothesis for the relationship above may be related to the inclination of the source,which may require a high inclination to explain *** relationships between QPO frequency and QPO rms,hardness,total fractional rms and count rate have also been found in other transient sources,which can indicate that the origin of type-C QPOs is non-thermal.

关键词： X-ray binaries black hole candidate QPO EXO 1846–031

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： Jie Wu Shu-wei Duan Hong-tao Yang Yue-yi Deng wei Li Ya-ni He Zhao-hui Ni Yong-li Zhan shan Lin zhi-yong Guo Jun Zhu Jing-ai Fang Xu-sheng Liu Li-hua Wang Rong Wang Nian-song Wang xiao-hong Cheng Li-qun He Ping luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu Chen Wen-hu Liu Hong-li Lin Meng Liang Lu Ma Ming Chen Li-qun Song Jian Chen Qing Zhu Chang-ying Xing Yun Li Ji-ning Gao Rong-shan Li Ying Li Hao Zhang Ying Lu Qiao-ling Zhou Jun-zhou fu Qiang He Guang-yan Cai xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(P<0.001)greater reduction in urine protein *** with the losartan potassium 100 mg group,the SYKFT plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li luo Yong-Heng Zhao Gang Zhao Li-Cai Deng xiao-wei Liu Yi-Peng Jing Gang Wang Hao-Tong Zhang Jian-Rong Shi xiang-Qun Cui Yao-Quan Chu Guo-Ping Li Zhong-Rui Bai Yue Wu Yan Cai Shu-Yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-yuan Chen Jian-Jun Chen Kun-Xin Chen Li Chen Xue-Lei Chen xiao-Yan Chen Ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong Bing Du Dong-wei Fan Lei Feng Jian-Ning fu Peng Gao Xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-Wen Han Bo-Liang He Jin-Liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-Wen Hu zhi-Ying Huo Lei Jia Fang-Hua Jiang xiang Jiang zhi-Bo Jiang Ge Jin xiao Kong Xu Kong Ya-Juan Lei Ai-Hua Li Chang-Hua Li Guang-wei Li Hai-Ning Li Jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li Yan Li Yin-Bi Li Ye-Ping Li yuan Liang Chien-Cheng Lin Chao Liu Gen-Rong Liu Guan-Qun Liu zhi-Gang Liu Wen-zhi Lu Yu luo Yin-Dun Mao Heidi Newberg Ji-Jun Ni Zhao-xiang Qi Yong-Jun Qi Shi-Yin Shen Huo-Ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-Jun Su Zheng-Hong Tang Qing-Sheng Tao yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang Hai Wang Hong-Chi Wang Jian Wang Jia-Ning Wang Jian-Ling Wang Jian-Ping Wang Jun-Xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang You Wang Yue-Fei Wang You-Fen Wang Peng wei Ming-zhi wei Hong Wu Ke-Fei Wu Xue-Bing Wu Yu-Zhong Wu xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu Yan Xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang Hui-Qin Yang Ming Yang Zheng-Qiu Yao Yong Yu Hui yuan Hai-Bo yuan Hai-Long yuan wei-Min yuan Chao Zhai En-Peng Zhang Hua-wei Zhang Jian-Nan Zhang Li-Pin Zhang wei Zhang Yong Zhang Yan-Xia Zhang Zheng-Chao Zhang Ming Zhao Fang Zhou Xu Zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in June 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in June 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-Bin Ling Qiao-Nan shan Xu-Yong wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min Ding zhi-Dan Xu Lai-Bang luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun Zhang Zhao-Jie Su zhi-Hai Peng Ren Lang Tao Jiang Qiang He Lin-Sen Ye Yang Yang Yu-Ting He Wen-zhi Guo Liu-Gen Lan Xu-Yong Sun Dong Chen zhi-Shui Chen Da-wei Zhou Shao-Jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu wei Rao Jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-Dong Wu Chang-Jiang Lu Cai-De Lu Dong-Hua Zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng Jun-Jie Li Wen-Tao Jiang Jian-Hua Li Quan-Bao Zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song zhi-Ren fu wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie luo Zhong-Zhou Si Bin Xie xiao-Shun He zhi-Yong Guo Shu-Sen Zheng xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion